Erlotinib as standard adjuvant therapy for resectable EGFR mutation-positive non-small cell lung cancer

Affiliations

Editorial

Satomi Tanaka et al. Transl Lung Cancer Res. 2019 Dec.

. 2019 Dec;8(Suppl 4):S369-S372.

doi: 10.21037/tlcr.2019.06.05.

¹ Department of Pulmonary Medicine, Kyoto Prefectural University of Medicine, Kyoto, Japan.

No abstract available

Conflict of interest statement

Conflicts of Interest: The authors have no conflicts of interest to declare.

Erlotinib versus vinorelbine plus cisplatin as adjuvant therapy in Chinese patients with stage IIIA EGFR mutation-positive non-small-cell lung cancer (EVAN): a randomised, open-label, phase 2 trial.
Yue D, Xu S, Wang Q, Li X, Shen Y, Zhao H, Chen C, Mao W, Liu W, Liu J, Zhang L, Ma H, Li Q, Yang Y, Liu Y, Chen H, Wang C. Yue D, et al. Lancet Respir Med. 2018 Nov;6(11):863-873. doi: 10.1016/S2213-2600(18)30277-7. Epub 2018 Aug 24. Lancet Respir Med. 2018. PMID: 30150014 Clinical Trial.

1. Pignon JP, Tribodet H, Scagliotti GV, et al. Lung adjuvant cisplatin evaluation: a pooled analysis by the LACE Collaborative Group. J Clin Oncol 2008;26:3552-9. 10.1200/JCO.2007.13.9030 - DOI - PubMed
1. Douillard JY, Tribodet H, Aubert D, et al. Adjuvant cisplatin and vinorelbine for completely resected non-small cell lung cancer: subgroup analysis of the Lung Adjuvant Cisplatin Evaluation. J Thorac Oncol 2010;5:220-8. 10.1097/JTO.0b013e3181c814e7 - DOI - PubMed
1. Arriagada R, Auperin A, Burdett S, et al. NSCLC Meta-analyses Collaborative Group Adjuvant chemotherapy, with or without postoperative radiotherapy, in operable non-small-cell lung cancer: two meta-analyses of individual patient data. Lancet 2010;375:1267-77. 10.1016/S0140-6736(10)60059-1 - DOI - PMC - PubMed
1. Tsuboi M, Kato H, Nagai K, et al. Gefitinib in the adjuvant setting: safety results from a phase III study in patients with completely resected non-small cell lung cancer. Anticancer Drugs 2005;16:1123-8. 10.1097/00001813-200511000-00012 - DOI - PubMed
1. Goss GD, O'Callaghan C, Lorimer I, et al. Gefitinib versus placebo in completely resected non-small-cell lung cancer: results of the NCIC CTG BR19 study. J Clin Oncol 2013;31:3320-6. 10.1200/JCO.2013.51.1816 - DOI - PMC - PubMed